TrialPloS one2014

Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial.

Tetsuro Miyazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.